Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation

Walter Pae, T. X. Aufiero, P. W. Weldner, C. A. Miller, W. S. Pierce

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bleeding after insertion of ventricular assist devices is a common problem which carries a major risk of immediate and late complications. We evaluated the safety and efficacy of aprotinin in six patients undergoing staged heart transplantation and compared the results with those of six patients who received no aprotinin. The groups did not differ significantly with respect to age, gender, preoperative cause of cardiomyopathy, or cardiopulmonary bypass time. Patients treated with aprotinin had a significant reduction in postoperative chest tube drainage (743 ± 457 versus 2036 ± 1184 cc, respectively, for aprotinin therapy versus no therapy; p = 0.047). Blood transfusion requirements were reduced in patients treated with aprotinin (2.2 ± 2.2 versus 10.7 ± 7.1 U respectively, for aprotinin therapy versus no therapy; p = 0.038). No demonstrable serious side effects were attributed to the aprotinin treatment. We conclude that aprotinin is effective in reducing bleeding and transfusion requirements without increasing the incidence of clinically significant renal dysfunction or thromboembolic events.

Original languageEnglish (US)
Pages (from-to)811-816
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume13
Issue number5
StatePublished - Oct 13 1994

Fingerprint

Aprotinin
Heart-Assist Devices
Heart Transplantation
Therapeutics
Hemorrhage
Chest Tubes
Cardiopulmonary Bypass
Cardiomyopathies
Blood Transfusion
Drainage
Kidney
Safety
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Pae, Walter ; Aufiero, T. X. ; Weldner, P. W. ; Miller, C. A. ; Pierce, W. S. / Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation. In: Journal of Heart and Lung Transplantation. 1994 ; Vol. 13, No. 5. pp. 811-816.
@article{c16ac869c67a4d4fa7699384d6967c24,
title = "Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation",
abstract = "Bleeding after insertion of ventricular assist devices is a common problem which carries a major risk of immediate and late complications. We evaluated the safety and efficacy of aprotinin in six patients undergoing staged heart transplantation and compared the results with those of six patients who received no aprotinin. The groups did not differ significantly with respect to age, gender, preoperative cause of cardiomyopathy, or cardiopulmonary bypass time. Patients treated with aprotinin had a significant reduction in postoperative chest tube drainage (743 ± 457 versus 2036 ± 1184 cc, respectively, for aprotinin therapy versus no therapy; p = 0.047). Blood transfusion requirements were reduced in patients treated with aprotinin (2.2 ± 2.2 versus 10.7 ± 7.1 U respectively, for aprotinin therapy versus no therapy; p = 0.038). No demonstrable serious side effects were attributed to the aprotinin treatment. We conclude that aprotinin is effective in reducing bleeding and transfusion requirements without increasing the incidence of clinically significant renal dysfunction or thromboembolic events.",
author = "Walter Pae and Aufiero, {T. X.} and Weldner, {P. W.} and Miller, {C. A.} and Pierce, {W. S.}",
year = "1994",
month = "10",
day = "13",
language = "English (US)",
volume = "13",
pages = "811--816",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "5",

}

Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation. / Pae, Walter; Aufiero, T. X.; Weldner, P. W.; Miller, C. A.; Pierce, W. S.

In: Journal of Heart and Lung Transplantation, Vol. 13, No. 5, 13.10.1994, p. 811-816.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aprotinin therapy for insertion of ventricular assist devices for staged heart transplantation

AU - Pae, Walter

AU - Aufiero, T. X.

AU - Weldner, P. W.

AU - Miller, C. A.

AU - Pierce, W. S.

PY - 1994/10/13

Y1 - 1994/10/13

N2 - Bleeding after insertion of ventricular assist devices is a common problem which carries a major risk of immediate and late complications. We evaluated the safety and efficacy of aprotinin in six patients undergoing staged heart transplantation and compared the results with those of six patients who received no aprotinin. The groups did not differ significantly with respect to age, gender, preoperative cause of cardiomyopathy, or cardiopulmonary bypass time. Patients treated with aprotinin had a significant reduction in postoperative chest tube drainage (743 ± 457 versus 2036 ± 1184 cc, respectively, for aprotinin therapy versus no therapy; p = 0.047). Blood transfusion requirements were reduced in patients treated with aprotinin (2.2 ± 2.2 versus 10.7 ± 7.1 U respectively, for aprotinin therapy versus no therapy; p = 0.038). No demonstrable serious side effects were attributed to the aprotinin treatment. We conclude that aprotinin is effective in reducing bleeding and transfusion requirements without increasing the incidence of clinically significant renal dysfunction or thromboembolic events.

AB - Bleeding after insertion of ventricular assist devices is a common problem which carries a major risk of immediate and late complications. We evaluated the safety and efficacy of aprotinin in six patients undergoing staged heart transplantation and compared the results with those of six patients who received no aprotinin. The groups did not differ significantly with respect to age, gender, preoperative cause of cardiomyopathy, or cardiopulmonary bypass time. Patients treated with aprotinin had a significant reduction in postoperative chest tube drainage (743 ± 457 versus 2036 ± 1184 cc, respectively, for aprotinin therapy versus no therapy; p = 0.047). Blood transfusion requirements were reduced in patients treated with aprotinin (2.2 ± 2.2 versus 10.7 ± 7.1 U respectively, for aprotinin therapy versus no therapy; p = 0.038). No demonstrable serious side effects were attributed to the aprotinin treatment. We conclude that aprotinin is effective in reducing bleeding and transfusion requirements without increasing the incidence of clinically significant renal dysfunction or thromboembolic events.

UR - http://www.scopus.com/inward/record.url?scp=0028095611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028095611&partnerID=8YFLogxK

M3 - Article

C2 - 7528538

AN - SCOPUS:0028095611

VL - 13

SP - 811

EP - 816

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 5

ER -